Technical Analysis for RGEN - Repligen Corporation

Grade Last Price % Change Price Change
grade B 86.65 0.25% 0.22
RGEN closed up 0.25 percent on Tuesday, November 19, 2019, on 67 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical RGEN trend table...

Date Alert Name Type % Chg
New Uptrend Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Stochastic Reached Overbought Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Above Upper BB Strength 0.25%
Upper Bollinger Band Touch Strength 0.25%
180 Bullish Setup Bullish Swing Setup 2.34%

Older signals for RGEN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Repligen Corporation, a life sciences company, engages in the development, production, and commercialization of consumable products used in the process of manufacturing biological drugs. Its bioprocessing products are sold to various life sciences and biopharmaceutical companies worldwide. The company manufactures Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. It also supplies various growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, the company develops and markets its OPUS brand series of pre-packed ‘plug-and-play' chromatography columns, and provides ELISA test kits to ensure final product quality. Further, Repligen has a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and a orphan drug candidate in Phase 1 development. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Biotechnology Biopharmaceutical Life Sciences Natural Sciences Consumable Products Monoclonal Antibody Bioprocessing
Is RGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 99.25
52 Week Low 48.26
Average Volume 604,892
200-Day Moving Average 74.7126
50-Day Moving Average 79.6096
20-Day Moving Average 81.8215
10-Day Moving Average 83.43
Average True Range 2.3304
ADX 25.13
+DI 34.8672
-DI 12.007
Chandelier Exit (Long, 3 ATRs ) 81.0088
Chandelier Exit (Short, 3 ATRs ) 83.7362
Upper Bollinger Band 87.1421
Lower Bollinger Band 76.5009
Percent B (%b) 0.95
BandWidth 13.005384
MACD Line 1.515
MACD Signal Line 0.9761
MACD Histogram 0.5389
Fundamentals Value
Market Cap 3.23 Billion
Num Shares 37.3 Million
EPS 0.51
Price-to-Earnings (P/E) Ratio 169.90
Price-to-Sales 12.40
Price-to-Book 6.72
PEG Ratio 2.55
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 89.55
Resistance 3 (R3) 89.67 88.84 89.06
Resistance 2 (R2) 88.84 88.10 88.77 88.90
Resistance 1 (R1) 87.74 87.64 87.33 87.62 88.74
Pivot Point 86.91 86.91 86.70 86.84 86.91
Support 1 (S1) 85.81 86.17 85.40 85.69 84.56
Support 2 (S2) 84.98 85.71 84.91 84.40
Support 3 (S3) 83.88 84.98 84.24
Support 4 (S4) 83.76